Travere officer Heerma plans $525K stock sale

Form 144 reports planned and recent Rule 144 and 10b5-1 share sales by Travere Therapeutics officer Peter Heerma.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) insider Peter Heerma, an officer, filed a notice of proposed sale of common stock under Rule 144. The notice lists a planned sale of 8,282 shares of common stock on September 17, 2026, following option exercises for cash with the issuer.

The filing also lists prior Rule 10b5-1 plan sales of Travere Therapeutics common stock during the preceding three months, reflecting significant recent disposition activity by the same insider.

Key Figures

Shares proposed for sale: 8,282 shares Aggregate market value of proposed sale: $525,741.36 Prior 10b5-1 sale on September 16, 2026: 172,717 shares for $10,956,078.36 +3 more

6 metrics

Shares proposed for sale 8,282 shares Common stock listed for sale under Rule 144 on September 17, 2026

Aggregate market value of proposed sale $525,741.36 Value associated with 8,282 shares of common stock listed for sale

Prior 10b5-1 sale on September 16, 2026 172,717 shares for $10,956,078.36 Common stock sold pursuant to a 10b5-1 plan

Prior 10b5-1 sale on September 15, 2026 102,190 shares for $6,362,824.52 Common stock sold pursuant to a 10b5-1 plan

Issuer SEC file number 001-36257 Travere Therapeutics, Inc. SEC file number

Planned sale date September 17, 2026 Date listed for proposed Rule 144 sale and option exercise

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for PETER HEERMA 3611 Valley Centre Drive"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 09/17/2026 | Exercise of Stock Options | Issuer"

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services 1"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing report for Travere Therapeutics (TVTX)?

The filing reports that officer Peter Heerma has notified of a proposed sale of 8,282 shares of Travere Therapeutics common stock under Rule 144, in connection with stock option exercises for cash with the issuer on September 17, 2026.

How many Travere Therapeutics (TVTX) shares are proposed to be sold in this notice?

The notice lists a proposed sale of 8,282 shares of Travere Therapeutics common stock, related to an exercise of stock options with the issuer for cash, with a listed sale date of September 17, 2026.

What is the aggregate market value of the proposed TVTX share sale?

The filing shows an aggregate market value of $525,741.36 tied to the 8,282 shares of Travere Therapeutics common stock listed for sale through Morgan Stanley Smith Barney LLC, with an intended sale date of September 17, 2026 on NASDAQ.

What prior 10b5-1 plan sales by Peter Heerma in TVTX are disclosed?

The document lists two prior Rule 10b5-1 plan sales: 172,717 shares of common stock on September 16, 2026 for $10,956,078.36, and 102,190 shares on September 15, 2026 for $6,362,824.52.

Which broker is listed for the proposed Travere Therapeutics (TVTX) share sale?

The proposed Rule 144 sale of 8,282 shares of Travere Therapeutics common stock is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, with NASDAQ identified as the trading market.

What is the stated method of acquisition for the TVTX shares to be sold?

The shares listed for proposed sale are stated to be acquired through an exercise of stock options from the issuer, with the consideration described as cash, and an exercise date of September 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:30 PM Accepted by SEC EDGAR 09/17/2026 - 04:30 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001789617
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS INC
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive, Suite 300 San Diego CALIFORNIA 92130
Phone	8889697879
Name of Person for Whose Account the Securities are To Be Sold	PETER HEERMA
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	8282	525741.36	94261082	09/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/17/2026	Exercise of Stock Options	Issuer			8282	09/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for PETER HEERMA 3611 Valley Centre Drive, Suite 300 San Diego CA 92130	Common	09/16/2026	172717	10956078.36
10b5-1 Sales for PETER HEERMA 3611 Valley Centre Drive, Suite 300 San Diego CA 92130	Common	09/15/2026	102190	6362824.52

144: Remarks and Signature

Remarks
Date of Notice	09/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Peter Heerma
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)